{
    "nctId": "NCT04809844",
    "briefTitle": "Concurrent Paclitaxel and Radiotherapy After Adjuvant Doxorubicin and Cyclophosphamide for Stage 2 or 3 Breast Cancer",
    "officialTitle": "Retrospective Study of Concurrent Paclitaxel and Radiation Therapy After Adjuvant Doxorubicin and Cyclophosphamide Chemotherapy for Stage 2 or 3 Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Toxicity of concurrent paclitaxel & breast radiotherapy such as acute skin toxicities .",
    "eligibilityCriteria": "Inclusion criteria :\n\n* \u2022 This study will include women aged 18 years \\&older.\n* patients must be histologically diagnosed with breast cancer (ductal \\& others).\n* patients who underwent conservative breast surgery \\& modified radical mastectomy.\n* patients with stage ll\\&lll breast cancer.\n* patients who received (AC) as adjuvant treatment .\n\nExclusion Criteria:\n\n* patients with stage 1 or 4 breast cancer.\n* patients received adjuvant chemotherapy rather than (AC) .\n* patients with prior irradiation with thoracic region .\n* pregnancy or lactation .\n* patient with serious comorbid disease such as chronic obstructive pulmonary disease .",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}